Federal regulators announced Monday that all GLP-1 medications - including Ozempic, Wegovy, Zepbound and Mounjaro - must now carry a label warning about a rare eye condition that can cause permanent vision loss. The move follows an FDA review of clinical trial data and real-world safety reports spanning a dozen injectable and oral drugs in this class.
What the condition involves
The disorder, called non-arteritic anterior ischemic optic neuropathy (NAION), results from reduced blood flow to the optic nerve. The FDA said the underlying cause of this blood-flow disruption in GLP-1 users remains unknown, though the association has now been documented across the entire drug class, not just semaglutide-based products like Ozempic and Wegovy.
Symptoms include blurred vision, blind spots and distorted colors. The FDA advises anyone experiencing these signs while on a GLP-1 medication to contact a healthcare provider immediately, since the condition can progress and is generally not reversible.
How the risk was identified
FDA scientists launched their investigation after a 2024 medical paper linked semaglutide use to NAION cases. Dr. Joseph Rizzo, a neuro-ophthalmologist at Massachusetts Eye and Ear and co-author of that paper, told CBS News he had been sharing data with the agency for some time and was not surprised by the warning, though he did not know a decision was imminent.
An FDA analysis of more than 125 clinical trials found NAION occurred in about 6 per 100,000 patients taking a GLP-1 drug for at least a year, compared with fewer than 4 per 100,000 among those on a placebo or other glucose-lowering medications. For context, the American Academy of Ophthalmology estimates NAION already affects 2 to 10 per 100,000 adults over age 50 regardless of medication use, meaning the condition can occur independent of GLP-1 treatment.
Company and physician responses
Novo Nordisk, which makes Ozempic and Wegovy, said it "continues to believe the data do not establish a cause-and-effect relationship" but acknowledged the condition "can have a profound impact on patients and their families." Eli Lilly, maker of Zepbound and Mounjaro, said it is "carefully evaluating the update" and noted the FDA communication applies broadly to the drug class rather than citing findings specific to its products.
Rizzo said he does not advise patients to stop taking these medications, calling them "profoundly beneficial," but cautioned that once vision loss occurs, improvement is typically limited and doctors currently have no reliable way to reduce the risk. He added that the severity of vision loss in one eye does not predict what may happen in the other.